Novo Nordisk A/S (NOVO-B.CO): Deep Dive Research Report

April 2026 | Healthcare Sector

Table of Contents

1. What the Company Does
2. Business Segments
3. Products and Business Detail
4. Customers
5. Competitive Landscape
6. Industry
7. Growth Triggers
8. Key Risks
9. Walk the Talk
10. Scenarios

1. What the Company Does

Novo Nordisk makes injectable and oral drugs for serious, chronic metabolic diseases - primarily type 2 diabetes and obesity, and a smaller but meaningful portfolio for rare blood and hormone disorders. The mechanism is pharmacological: their drugs work by mimicking or enhancing the body's own metabolic signaling molecules to regulate blood sugar, body weight, and appetite. What separates them from most pharmaceutical companies is that they have been doing this in one specific biological domain - the pancreatic-hormone system - for over 100 years, and have built manufacturing, intellectual property, and clinical knowledge in that domain that most competitors cannot replicate quickly.

The company began in 1923 when August Krogh, a Danish Nobel Prize-winning physiologist, traveled to Toronto after insulin had just been discovered there. Krogh obtained rights to manufacture insulin in Scandinavia and returned to Denmark to found Nordisk Insulinlaboratorium with physician Hans Christian Hagedorn. Almost simultaneously, two former Nordisk employees - brothers Harald and Thorvald Pedersen - left to start their own insulin company, Novo Terapeutisk Laboratorium, in 1925. For over six decades, Novo and Nordisk competed in the same narrow therapeutic space. In 1989, recognizing that global competition against larger American and European firms required scale, the two companies merged into Novo Nordisk A/S.

The merger is relevant because it created the culture that drives the company today: obsessive focus on one disease area rather than diversification. While most major pharmaceutical companies became multi-therapeutic conglomerates through the 1990s and 2000s, Novo Nordisk deepened into metabolic disease. That decision has compounded massively. When the GLP-1 receptor agonist drug class emerged as both a superior diabetes treatment and an effective obesity medicine, Novo Nordisk was positioned better than anyone.

The core value proposition can be stated plainly: Novo Nordisk makes drugs that meaningfully change the progression of diseases that have historically been managed rather than reversed. Insulin kept diabetics alive; GLP-1 drugs like semaglutide can reduce blood sugar, body weight, cardiovascular events, kidney disease progression, and liver inflammation - all from one molecule. That biological breadth is not coincidental. It reflects the fact that obesity and metabolic syndrome are not isolated conditions; they are the upstream cause of many of the most common and expensive chronic diseases in developed countries. A drug that addresses the upstream condition effectively addresses many downstream ones.

Semaglutide - Novo Nordisk's dominant molecule today - works by mimicking GLP-1 (glucagon-like peptide-1), a hormone produced in the gut after eating. GLP-1 tells the pancreas to release insulin when blood sugar is high, tells the liver to stop releasing glucose, slows gastric emptying so you feel full longer, and works directly in the brain to reduce appetite. Natural GLP-1 degrades in minutes. Novo Nordisk's chemists modified its molecular structure - particularly by attaching a fatty acid chain that binds to albumin in the blood - so that semaglutide is only cleared from the body in about one week. That modification is what allows once-weekly dosing. It took roughly 15 years of iterative chemistry from Novo's earlier GLP-1 molecule (liraglutide, approved 2009) to semaglutide's U.S. approval in 2017.

The result is a company that today serves approximately 46 million people with diabetes and obesity globally through a portfolio anchored by a single molecule - semaglutide - sold under different brand names (Ozempic for diabetes, Wegovy for obesity, Rybelsus for oral diabetes), at different doses, and with expanding indications. It is an unusual situation in pharmaceuticals: one molecule generating the majority of one of the world's largest drug companies' revenue, with clinical evidence accumulating so broadly that new indications keep emerging. But it is also a structural concentration risk that underpins many of the key risks discussed later.

2. Business Segments

Novo Nordisk reports in three therapeutic segments. In 2024, Diabetes Care contributed approximately 71% of sales, Obesity Care approximately 22%, and Rare Disease approximately 7%. By 2025, Obesity Care had grown to approximately 27% as Wegovy continued to scale.

2.1 Diabetes Care

Diabetes Care is the foundational business - the segment that funded every drug development program that exists today and that has been operating continuously since 1923. It covers all pharmaceutical treatments Novo Nordisk sells for type 1 and type 2 diabetes: GLP-1 receptor agonists (the growth engine), insulins (the legacy cash cow), and combination products.

The core capability in diabetes is a century of insulin biology. Novo Nordisk invented modern insulin manufacturing infrastructure - purification techniques, recombinant DNA production, device engineering (the NovoLog insulin pen, FlexTouch), and cold chain distribution to over 80 countries. This is not something that can be replicated in a few years. Manufacturing insulin at pharmaceutical grade and at global scale requires validated processes, proprietary cell lines, sterile fill-and-finish capacity, and decades of regulatory relationships. The company has production facilities in Denmark, France, Brazil, China, and several other countries specifically built for this work.

Within Diabetes Care, the competitive dynamic has changed materially. Insulins - which include Tresiba (insulin degludec, once-daily basal), Levemir (insulin detemir), NovoRapid/NovoLog (rapid-acting aspart), NovoMix (premix aspart), and the iGlarLixi combination product Xultophy - are a mature, slowly declining category. Price erosion in U.S. insulin under government and payer pressure, along with structural competition from biosimilars (Sanofi's Lantus biosimilars, Eli Lilly's Basaglar), has compressed insulin margins. The company's launch of Awiqli (insulin icodec) - the world's first once-weekly basal insulin, approved in the EU - was meant to reinvigorate the insulin franchise. However, Awiqli received a complete response letter from the FDA in 2024 citing manufacturing concerns and review of the Type 1 indication, delaying its U.S. debut.

The GLP-1 diabetes franchise - Ozempic (once-weekly injectable semaglutide), Rybelsus (daily oral semaglutide), and legacy Victoza (daily injectable liraglutide, now declining) - is the growth engine of this segment. Ozempic achieved 22% global growth in 2024 and maintains approximately 34% of the total GLP-1 diabetes market globally. Rybelsus, the oral formulation, showed greater than 60% growth in International Operations in 2024 and represents the only oral GLP-1 that has been commercially validated at scale. The SELECT cardiovascular outcomes data (20% reduction in major adverse cardiovascular events published in the NEJM) expanded Ozempic's clinical use beyond glycemic control - it is now reimbursed under Medicare Part D for cardiovascular risk reduction in patients with obesity, even without a formal diabetes diagnosis in some cases.

This segment exists separately because the customer set, sales force infrastructure, reimbursement mechanisms, and physician relationships are distinct from obesity. Endocrinologists, primary care physicians, and diabetologists are the primary prescribers. The formulary negotiation process goes through pharmacy benefit managers focused on the diabetes category. And the regulatory requirements - outcomes trials, glycemic endpoints, cardiovascular safety studies - are specific to diabetes.

2.2 Obesity Care

Obesity Care is the fastest-growing and increasingly dominant segment, having gone from a small, supply-constrained business in 2022 to generating over DKK 82 billion (approximately $12 billion USD equivalent) in 2025, up 31% at constant exchange rates that year. Globally, it has become one of the largest pharmaceutical businesses in history for a single indication.

Wegovy (semaglutide 2.4mg, once-weekly subcutaneous injection) is the primary product. It is the same semaglutide molecule as Ozempic but at a higher dose and with a distinct FDA approval for chronic weight management - a regulatory classification that matters enormously for insurance reimbursement. In the STEP 1 trial, Wegovy produced approximately 15% average body weight loss versus 2.4% placebo. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events in obese non-diabetic patients, a landmark result that triggered Medicare Part D coverage for obesity medicine for the first time in history, and led to the drug being added to the World Health Organization's Essential Medicines List in 2023.

The core capability of the Obesity Care segment is the clinical evidence dossier behind semaglutide at the 2.4mg dose - STEP 1-4, SELECT, SURMOUNT comparisons, renal outcomes data, heart failure data, MASH data. No competitor has a comparably broad evidence base for a single obesity drug. This breadth makes it very difficult for payers to deny coverage on clinical grounds, and it gives Novo Nordisk a differentiated conversation with physicians beyond "how much weight does the patient lose."

In January 2026, Novo Nordisk launched oral Wegovy (semaglutide 25mg tablet) in the United States - the first oral GLP-1 approved for obesity in the world. The OASIS 4 trial showed 13.6% weight loss versus 2.2% placebo. While the weight loss is less than the injectable, the market for patients who prefer a pill over weekly injections is enormous, and management reported 50,000 weekly prescriptions in the first week of launch, described by Dave Moore as "over twice that of any prior anti-obesity drug launch in the United States." Approximately 30% of those prescriptions came through self-pay cash channels.

The segment also includes Saxenda (injectable liraglutide 3mg), a once-daily obesity drug approved in 2014 that is now being cannibalized by Wegovy. Saxenda continues to generate revenue internationally where Wegovy is not yet launched but is a structurally declining product.

Obesity Care exists as a separate reporting segment because it serves a different patient population (non-diabetic obese individuals), different payers and formularies (anti-obesity medicine carve-outs vs. diabetes drug lists), different physician champions (weight management specialists, cardiologists, primary care), and carries different regulatory requirements (longer-duration safety data, REMS programs historically).

2.3 Rare Disease

Rare Disease is the smallest but strategically important segment, representing approximately 7% of 2024 sales (approximately DKK 19 billion). It covers two distinct therapeutic domains: rare bleeding disorders and rare endocrine disorders (primarily growth hormone deficiency and related conditions).

In rare bleeding disorders, Novo Nordisk has been a leading player since the 1980s. The flagship product is NovoSeven RT (eptacog alfa, recombinant Factor VIIa), used to treat bleeding episodes in haemophilia A and B patients who have developed inhibitors (antibodies that block standard clotting factor treatments), as well as patients with Glanzmann's thrombasthenia or acquired haemophilia. NovoSeven is a bypass therapy - it doesn't replenish the missing clotting factor but bypasses the deficiency altogether by activating the coagulation cascade at a later point. It is a high-value medicine with very small patient populations and high pricing power.

The broader haemophilia portfolio includes NovoEight (extended half-life recombinant Factor VIII for haemophilia A), Rebinyn (glycoPEGylated Factor IX for haemophilia B), and Esperoct (turoctocog alfa pegol, extended half-life Factor VIII). The pipeline is adding Mim8 - a bispecific antibody that mimics the cofactor function of Factor VIII without being a Factor VIII protein itself, making it effective even in patients with inhibitors. Mim8 achieved Phase 3 results showing 97% and 99% reductions in bleeding rates for weekly and monthly dosing respectively and has been submitted for approval in the EU and Japan.

In rare endocrine, Norditropin (somatropin recombinant human growth hormone) is the main product, used for pediatric growth failure from multiple causes and adult growth hormone deficiency. Sogroya (somapacitan-beco), a once-weekly long-acting growth hormone, was approved for adults in 2021 and has received regulatory submissions for pediatric indications.

Why does Rare Disease exist alongside the metabolic business? The biological roots are shared: both diabetes and rare endocrine disorders involve protein hormones (insulin, growth hormone), and Novo Nordisk developed expertise in recombinant protein manufacturing that transferred directly. NovoSeven was developed in the late 1980s using the same recombinant DNA technology platform Novo used for insulin. The manufacturing expertise, regulatory pathway knowledge, and global specialty distribution networks are shared. This segment is not a random acquisition - it is a natural extension of the founding competency.

Strategically, management has been explicit that Rare Disease will remain focused on blood and endocrine disorders. The segment is slower-growing (9% in 2024) but capital-light relative to the GLP-1 build-out, generates healthy margins, and provides therapeutic diversity.

3. Products and Business Detail

Core Molecule: Semaglutide

Semaglutide is a GLP-1 receptor agonist. Its chemical structure is a 31-amino acid peptide, derived from native human GLP-1 but with two amino acid substitutions (one to resist degradation by the enzyme DPP-4, one to reduce albumin binding at the protein backbone level) and the addition of a C18 fatty diacid chain at lysine-26. The fatty acid chain is what creates the molecule's week-long half-life: it binds to albumin in the blood, which acts as a depot, slowly releasing semaglutide and protecting it from kidney clearance. Making this molecule at commercial scale required Novo Nordisk to develop novel solid-phase peptide synthesis infrastructure in Denmark, specifically at its Kalundborg active pharmaceutical ingredient (API) site. The chemistry is complex: the final product requires multiple synthesis steps, careful purification by chromatography, and a lyophilization or liquid formulation stage. Novo Nordisk has been building Kalundborg capacity continuously since 2021 and has committed over $11 billion in new API manufacturing infrastructure globally.

Products by Category

GLP-1 Diabetes

Ozempic (semaglutide injection 0.5mg, 1mg, 2mg) - Once-weekly subcutaneous injection approved for type 2 diabetes in 2017 (U.S.), with subsequent approvals in 80+ countries. Now also carries a U.S. label for reduction of cardiovascular events in adults with T2D and established cardiovascular disease. Available in 0.5mg and 1mg doses as standard T2D treatment and 2mg for those needing greater glycemic control. Comes in a pre-filled pen injector. The world's best-selling individual diabetes drug in 2024.

Rybelsus (oral semaglutide 3mg, 7mg, 14mg) - The only approved oral GLP-1 receptor agonist globally. Absorption is a challenge because GLP-1 is a peptide that would normally be destroyed by stomach acid. Novo Nordisk solved this by co-formulating semaglutide with sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC), an absorption enhancer that creates a local pH environment in the stomach allowing transmucosal absorption before the drug reaches the more destructive intestinal environment. Patients must take Rybelsus on an empty stomach with minimal water, wait 30 minutes before eating or drinking. The bioavailability is low (approximately 1%) but the absolute dose absorbed is clinically effective. Rybelsus is available in over 40 countries and is a significant growth driver in International Operations where injectable product launches have been more constrained.

Victoza (liraglutide 1.2mg, 1.8mg) - Daily injectable GLP-1 approved in 2009. First major commercial GLP-1 product, now being displaced by Ozempic. Still used where once-weekly dosing is not yet reimbursed or in patients who prefer daily dosing.

GLP-1 Obesity

Wegovy (semaglutide injection 2.4mg) - Once-weekly subcutaneous injection for chronic weight management. Available in starter doses (0.25mg, 0.5mg, 1mg, 1.7mg) that titrate up over 16-20 weeks to the 2.4mg maintenance dose. The titration protocol exists because gastrointestinal side effects (nausea, vomiting) are most common during dose escalation; slower titration reduces dropout. Initial supply constraints post-launch were partly caused by this: the 0.25mg initiation dose was disproportionately short because of demand surge. By 2024, weekly U.S. prescriptions had reached approximately 200,000. Wegovy carries indications for weight management plus reduction of cardiovascular events (following SELECT), and received FDA approval for MASH (metabolic dysfunction-associated steatohepatitis) treatment in August 2025 based on the ESSENCE trial.

Oral Wegovy (semaglutide tablet 25mg) - Launched in the United States in January 2026 after FDA approval in December 2025. The OASIS 4 trial showed 13.6% mean weight loss at 68 weeks. The same SNAC absorption technology used in Rybelsus is used here, but at 2.5x the tablet dose. Approximately 50,000 weekly prescriptions were written in the first week of launch. Commercial coverage secured with CVS/Caremark, Prime, Optum, and Anthem. This is a pivotal product for Novo Nordisk as it expands access to patients who would not self-inject and provides a competitive response to the oral GLP-1 programs in development at Eli Lilly (orforglipron) and others.

Saxenda (liraglutide 3mg) - Daily injectable obesity drug, approved 2014. Being actively displaced by Wegovy and approaching commercial end-of-life in developed markets. Still important in certain markets where Wegovy launch is pending.

Insulins

Tresiba (insulin degludec) - A once-daily ultra-long-acting basal insulin with a half-life exceeding 24 hours due to its unique self-aggregating fatty acid structure that creates a subcutaneous depot. Clinical advantage: more stable glucose control overnight and lower hypoglycemia rates than glargine (Lantus). Used in both T1D and T2D.

Levemir (insulin detemir) - Once or twice daily basal insulin, older product, losing ground to Tresiba.

NovoRapid/NovoLog (insulin aspart) - Rapid-acting mealtime insulin. Faster onset than regular human insulin.

NovoMix (biphasic insulin aspart) - Premix for patients who prefer two injections per day over basal-bolus regimens.

Xultophy (insulin degludec + liraglutide) - Combination pen delivering both basal insulin and a GLP-1 receptor agonist in a single daily injection. An elegant solution for patients who need both but face injection burden.

Awiqli (insulin icodec) - The world's first once-weekly basal insulin. Approved in the EU and several other markets. U.S. FDA complete response letter received in 2024 required manufacturing remediation and additional data; U.S. launch timeline uncertain.

IcoSema (insulin icodec + semaglutide combination) - Once-weekly combination filed for regulatory review in H2 2024. Achieves HbA1c reductions superior to semaglutide alone. If approved, this is potentially the most convenient type 2 diabetes treatment on the market: one weekly injection covers both basal insulin and GLP-1.

Rare Disease - Haemophilia

NovoSeven RT (eptacog alfa, recombinant Factor VIIa) - Bypass therapy for haemophilia A/B with inhibitors, congenital Factor VII deficiency, Glanzmann's thrombasthenia. Administered intravenously. High cost, small patient populations. Faces competitive pressure from Roche's emicizumab (Hemlibra), which has a simpler subcutaneous dosing schedule for haemophilia A with inhibitors.

NovoEight (turoctocog alfa) - Standard recombinant Factor VIII for haemophilia A without inhibitors.

Rebinyn (nonacog beta pegol) - Extended half-life Factor IX for haemophilia B. Once-weekly or every two-week dosing.

Esperoct (turoctocog alfa pegol) - Extended half-life Factor VIII, allowing dosing every four days.

Mim8 (marstacimab) - A bispecific antibody that mimics the cofactor function of Factor VIII by simultaneously binding both Factor IXa and Factor X, bridging them to enable the coagulation cascade even in the absence of functional Factor VIII. It works by a completely different mechanism from replacement factors, meaning it is effective in both haemophilia A patients with and without inhibitors. In the FRONTIER 2 Phase 3 trial, Mim8 achieved 97% and 99% median annualized bleed rate reductions. Filed for approval in the EU and Japan in 2024-2025. If approved, Mim8 would become the first new mechanism entry from Novo Nordisk into the haemophilia market in decades and would compete directly with Hemlibra in the inhibitor population.

Rare Disease - Growth Hormone

Norditropin (somatropin) - Recombinant human growth hormone, once-daily injection. Indicates for pediatric growth failure from multiple causes and adult GHD. Market leader in many countries but faces competition from biosimilars and from Novo's own next-generation product.

Sogroya (somapacitan-beco) - Once-weekly long-acting growth hormone analog. Adult indication approved. Pediatric indication filed after successful REAL pediatric trial showing non-inferiority to Norditropin.

Manufacturing

Novo Nordisk's manufacturing footprint is one of the most capital-intensive build-outs in the pharmaceutical industry today. The company invested approximately DKK 45 billion (around $6.7 billion) in capital expenditure in 2024, and guided DKK 55-65 billion for 2025-2026 per year. The scale of this commitment - almost double that of any prior year - reflects the recognition that supply was the primary constraint on Wegovy's commercial growth in 2022-2023.

The API (active pharmaceutical ingredient) network is anchored at Kalundborg, Denmark, where Novo Nordisk has been manufacturing since the 1920s. Novo is building a new 170,000 square-meter multi-product API facility in Kalundborg, representing one of the largest pharmaceutical manufacturing construction projects in history, at a cost exceeding $11 billion. Additional API sites operate in France and are being expanded in Brazil.

The fill-and-finish network - where bulk API is formulated into the final injectable product, filled into cartridges, assembled into pens, and packaged - expanded from 11 to 14 global sites in December 2024 when Novo Nordisk acquired three sites from Catalent (located in Italy, Belgium, and the United States) for approximately $11 billion. This was part of a broader transaction where Novo Holdings (the parent holding company) acquired all of Catalent and then passed three strategic fill-finish sites to Novo Nordisk.

The pen device engineering is done at Novo Nordisk's devices facility in Hillerød, Denmark. The company holds substantial intellectual property in drug delivery device design - the FlexTouch and FlexPen systems are precision-engineered mechanisms that allow accurate dosing, patient-friendly operation, and cold-chain stability.

Geographies

North America Operations (predominantly U.S.) accounted for approximately 58% of 2024 sales and delivered 30% growth at constant exchange rates. The U.S. is by far the most profitable market due to its higher net prices, favorable formulary coverage for branded drugs, and the premium placed on GLP-1 differentiation by payers.

International Operations (rest of world, approximately 42% of 2024 sales) grew 19% at constant exchange rates in 2024. Europe, China, and Japan are the largest markets outside the U.S. Rybelsus has been a particularly strong international growth driver because it does not require the fill-and-finish capacity that injectable Wegovy does. Japan has been a notable growth market given its large T2D population and favorable pricing for GLP-1 drugs. Latin America (Brazil in particular) and Southeast Asia represent earlier-stage growth markets.

4. Customers

Novo Nordisk's products are prescribed by physicians and dispensed through pharmacies or hospitals - but the actual economic decision (whether the drug is on formulary and at what cost to the patient) is made by payers. Understanding who really buys is therefore a two-layer problem: who prescribes, and who pays.

Prescribers

For diabetes, the primary prescribers are endocrinologists (who handle complex or insulin-requiring patients), primary care physicians (who manage the bulk of routine T2D patients), and cardiologists (increasingly, following the SELECT data showing Ozempic's cardiovascular benefit). The prescriber base for Ozempic is very broad - approximately 100,000+ healthcare providers wrote a prescription in 2024 in the U.S. alone. This breadth means Novo Nordisk cannot rely on specialist-only sales and requires a large primary care sales force.

For obesity, the prescriber base is more diverse and historically thinner. Before SELECT, most obesity medicine was prescribed by weight management specialists and endocrinologists. Post-SELECT, cardiologists began adopting Wegovy for cardiovascular risk reduction, and primary care began receiving prior authorization support tools that made prescribing more accessible. The introduction of telehealth platforms (Hims & Hers, Ro, LifeMD) as prescribing partners in 2025 - following the compounding crisis - dramatically expanded the prescriber base to include providers operating entirely within digital health ecosystems.

For rare disease (haemophilia, growth hormone), prescribers are subspecialists: haematologists at Haemophilia Treatment Centers (HTCs), pediatric endocrinologists for growth hormone. This is a traditional specialty model with deep physician relationships built over decades.

Payers

In the United States, payers are the dominant force. The three major pharmacy benefit managers - CVS/Caremark, OptumRx, and Prime Therapeutics - control formulary access for hundreds of millions of covered lives. Express Scripts (Cigna) is the fourth significant PBM. Novo Nordisk negotiates rebate agreements with these PBMs that determine where on the formulary Ozempic, Wegovy, and Rybelsus sit and what the patient cost-sharing looks like.

In 2024, Novo Nordisk reported that approximately 80% of U.S. Wegovy patients were paying $25 or less out-of-pocket per month, largely through commercial insurance and Novo's own co-pay assistance programs. This is a deliberately managed access strategy: making the drug affordable at the patient level drives adherence and real-world outcomes data, which then reinforces payer coverage decisions.

Medicare Part D is now a critical and expanding payer channel. The SELECT trial's cardiovascular outcomes data enabled Medicare coverage for Wegovy in patients with obesity and established cardiovascular disease. CMS has launched the BALANCE model, a pilot program with voluntary payer and Medicaid participation, capping patient out-of-pocket spending at $50/month for GLP-1 medications. For obesity specifically, Medicare Part D coverage for anti-obesity medicines is expected to expand mid-2026, opening access for approximately 30 million Medicare-eligible obese patients - a population that has historically had no drug coverage for weight management. However, this is double-edged: more volume at lower net prices.

Outside the U.S., payer dynamics vary enormously. In Europe, reimbursement is handled by national health systems (NHS in the UK, Assurance Maladie in France, GKV in Germany) with health technology assessment processes. Wegovy's obesity indication required demonstrating cost-effectiveness including cardiovascular outcomes. Germany added it to formulary in 2023. The UK's NICE issued guidance supporting Wegovy reimbursement for specific patient populations. China's National Medical Products Administration approval and subsequent National Reimbursement Drug List negotiations determine pricing in that market.

Why Customers Choose Novo Nordisk

For prescribers, the reasons are clinical: semaglutide has more approved indications and more outcomes data than any competing GLP-1. The SELECT trial, FLOW kidney trial, SOUL oral cardiovascular trial, ESSENCE MASH trial - no other obesity or diabetes drug has this evidence depth. The once-weekly dosing is practically superior to daily injection or twice-daily oral. The pen delivery device is user-tested and intuitive.

For payers, the decision is primarily economic: semaglutide at sufficient rebate generates lower cardiovascular hospitalization rates, lower dialysis costs, lower bariatric surgery costs. The SELECT data quantifies this reduction (20% fewer MACE events) in a way that makes cost-effectiveness modeling tractable. Novo Nordisk has heavily invested in health economics teams to make this argument rigorously.

Switching Costs

Switching costs in pharmaceuticals are moderate but real. A type 2 diabetes patient stabilized on Ozempic who is switched to a competitor's GLP-1 faces re-titration, temporary tolerability issues, and possible efficacy differences. The physician must write a new prescription, the pharmacy must verify insurance approval, and the payer must process a new prior authorization. None of these are technically prohibitive, but they create friction. The bigger switching cost is physician inertia: a doctor familiar with Ozempic's side effect profile, dosing, and patient outcome patterns is unlikely to change unless a competitor offers meaningfully superior clinical results or dramatically better pricing.

For haemophilia products, switching costs are very high. Patients at Haemophilia Treatment Centers build relationships with specific therapies over years; changes require clinical justification and close monitoring. Inhibitor patients in particular - those using NovoSeven - have been through difficult clinical histories and are unlikely to switch without compelling evidence.

Concentration

The U.S. market represents an outsized portion of revenue (approximately 58% in 2024) and specifically the three major PBMs collectively control formulary decisions affecting the majority of that business. This means Novo Nordisk's U.S. revenue is implicitly concentrated in a few institutional negotiating relationships. An adverse formulary decision (removing Wegovy from preferred status in favor of tirzepatide, for example) would be commercially significant. This risk has materialized partially: Eli Lilly's Zepbound has been gaining preferred positioning on certain formularies at the expense of Wegovy.

5. Competitive Landscape

Structure of the Market

The GLP-1 market is currently a two-player oligopoly with one incumbent (Novo Nordisk) and one highly competitive challenger (Eli Lilly). This is unusual for a $70+ billion drug market because the barrier to entry - conducting GLP-1 clinical trials of sufficient size and duration to generate the kind of outcomes data required for broad reimbursement - keeps smaller companies out for a decade or more after they initiate programs. But several larger companies are working through that pipeline.

Eli Lilly (Mounjaro/Zepbound - tirzepatide)

Tirzepatide is a "dual agonist" - it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual activation produced weight loss of up to 21% in the SURMOUNT trials, compared to semaglutide's approximately 15% in STEP 1, and approximately 17.5% with semaglutide 2.4mg in the STEP UP trial. Tirzepatide is approved for T2D as Mounjaro and for obesity as Zepbound. It is also now the world's best-selling drug by some measures, having achieved blockbuster status in Q2 2024 with exceptional quarterly growth rates.

By Q2 2025, Eli Lilly had overtaken Novo Nordisk in global GLP-1 market share - 57% versus Novo's declining share. Novo Nordisk lost approximately 9 percentage points of global market share in the 12 months to Q3 2025. Lilly's advantages: superior average weight loss data, a lower-priced vial format enabling broader access, and supply that was available when Novo's supply was constrained in 2022-2023. Those supply constraints drove trial of Mounjaro/Zepbound among patients and physicians who might otherwise have stayed on semaglutide.

Lilly also has an oral GLP-1 program (orforglipron) in Phase 3 that directly competes with Novo's oral Wegovy 25mg launch. Orforglipron is a small molecule (not a peptide), which may give it manufacturing cost advantages and does not require the SNAC delivery system. Phase 3 data readout is expected in 2025-2026.

Where does Novo win against Lilly? Breadth of evidence - Ozempic/Wegovy's SELECT, FLOW, SOUL, ESSENCE data library is more comprehensive than tirzepatide's. Rybelsus is approved and generating meaningful commercial revenue in oral diabetes with no equivalent from Lilly (yet). The Foundation ownership structure gives Novo Nordisk more strategic patience - it does not need to maximize near-term earnings per share. And in International Operations, Novo has had a longer global presence; Ozempic is available in approximately 80 countries versus Mounjaro/Zepbound's smaller international footprint.

AstraZeneca

AstraZeneca's GLP-1 legacy products (Byetta, Bydureon - exenatide) are irrelevant to current competition. However, AstraZeneca has acquired rights to cotadutide (a GLP-1/glucagon dual agonist), is developing MASH treatments including efruxifermin (a partnership with Akero - though Novo Nordisk made an acquisition bid for Akero in 2025), and has broad metabolic ambitions. AstraZeneca is a real longer-term competitor, particularly in international markets, but does not yet have a direct competitive GLP-1 product.

Sanofi

Sanofi's insulin franchise (Lantus, Toujeo - insulin glargine biosimilar) competes directly with Novo Nordisk's insulin products. In the U.S. insulin market, Lantus biosimilars created significant pricing pressure. In GLP-1, Sanofi's Soliqua (glargine + lixisenatide) is a legacy combination product with minimal market impact today. Sanofi has no near-term GLP-1 obesity program.

Roche (in haemophilia)

Roche's emicizumab (Hemlibra) is the dominant new mechanism haemophilia A treatment. It is a bispecific antibody that mimics Factor VIII's cofactor function - the same approach as Novo Nordisk's Mim8, which Novo built specifically to compete in this space. Hemlibra achieved approximately 50% of haemophilia A patients with inhibitors on subcutaneous dosing with excellent bleed reduction. Mim8's differentiator is the Phase 3 data showing even higher bleed rate reductions (97-99%) with monthly dosing, and its activity in haemophilia B (which Hemlibra does not cover). The inhibitor-patient population overlap with Hemlibra is real competitive pressure for NovoSeven and Esperoct.

Compounding Pharmacies (the structural disruptor of 2023-2025)

This deserves its own entry because it was the dominant competitive dynamic in 2025. When semaglutide was on the FDA drug shortage list (as it was from 2022 through early 2025), U.S. federal law permitted compounding pharmacies to produce copies of the active ingredient. An estimated 3.7 million Americans were obtaining compounded semaglutide at $150-400/month versus branded Wegovy's ~$1,349 list price. Management described compounding as the "largest single factor" impacting Novo's U.S. market share through H1 2025.

The FDA removed semaglutide from the shortage list in February 2025. Federal law then required compounders to wind down production - 503A pharmacies by April 22, 2025, and 503B outsourcing facilities by May 22, 2025. Novo Nordisk has filed approximately 120 lawsuits against compounders continuing to operate illegally after those deadlines. But Q3 2025 management commentary acknowledged that "unsafe and unlawful mass compounding has continued" even after the legal deadline, and that Novo's market research indicated over 1 million U.S. patients remained on compounded GLP-1s. This is both a market share issue and a patient safety issue.

Barriers to Entry

The barriers to entering the GLP-1 therapeutic market at meaningful scale are genuinely high, but not impenetrable:

Clinical trial requirement: A competitive obesity drug requires at minimum a Phase 3 trial of 68+ weeks duration enrolling 1,000-2,000+ patients, plus a 3-5 year cardiovascular outcomes trial for full label and broad reimbursement. This means a new entrant today cannot have a competitive product for at least 5-8 years.

Manufacturing complexity: Peptide API synthesis at commercial scale is technically complex and capacity-constrained globally. Even Novo Nordisk, with decades of manufacturing experience, has been supply-constrained. New entrants face the same build-out challenge.

Evidence library: Semaglutide's breadth of indication (T2D, obesity, cardiovascular, kidney, liver, heart failure) took 20+ years of investment. Competing on breadth requires running equivalent trials across all those indications - each costing hundreds of millions of dollars.

Regulatory relationships: FDA and EMA familiarity with a drug class matters for approval timelines. Novo Nordisk and Eli Lilly have established regulatory teams specialized in GLP-1 submissions.

Payer relationships: Formulary access requires rebate negotiations with PBMs. A new entrant without an established portfolio has less leverage.

The barrier is not infinite - Eli Lilly overcame it. And Pfizer, Amgen, Structure Therapeutics, AstraZeneca, and others are running programs. But none of the smaller-company programs will generate the cardiovascular outcomes data required for broad Medicare reimbursement within the next 5 years.

6. Industry

What Drives Demand

The fundamental demand driver for Novo Nordisk's products is disease prevalence. As of 2024, approximately 540 million people have type 2 diabetes globally, and over 880 million adults and 159 million children are living with obesity. These are not static numbers. The global obesity and T2D prevalence has been rising for 40 years without meaningful pharmaceutical intervention. The key insight is that drug therapy previously addressed only the downstream complications (cardiovascular disease, kidney failure) rather than the upstream cause (obesity itself). GLP-1 receptor agonists are the first class of drug that credibly addresses the upstream disease at sufficient efficacy to impact metabolic trajectories.

Beyond prevalence, a behavioral demand driver is increasing acceptance of pharmaceutical treatment for obesity. For decades, obesity was culturally framed as a lifestyle failure rather than a medical disease. GLP-1 drugs are changing that framing - both medically and socially. This cultural shift is expanding the treatment-seeking population rapidly.

Within diabetes, demand growth is slower but structural: T2D prevalence continues rising in Asia (particularly India, China) and in lower-middle-income markets as diets westernize. This drives long-term GLP-1 and insulin volume.

Industry Size

The global GLP-1 receptor agonist market was estimated at approximately $70 billion in 2025 and is projected to grow to approximately $200 billion by 2033 at a CAGR of approximately 13%. The obesity-specific GLP-1 market, which was smaller (approximately $8-10 billion in 2024), is projected to exceed $66 billion by 2035.

The broader pharmaceutical addressable market is even larger when considering the indications semaglutide is pursuing: MASH (metabolic dysfunction-associated steatohepatitis) affects an estimated 6-8% of the global adult population and currently has very limited treatment options; chronic kidney disease affects approximately 850 million people globally; heart failure with preserved ejection fraction affects millions with no approved medical treatment beyond standard care.

Regulatory Environment

The U.S. FDA has generally been supportive of GLP-1 drug development, though specific issues have arisen:

• The Inflation Reduction Act (IRA) allows Medicare to negotiate drug prices directly with manufacturers starting with products selected for the Small Molecule Drug Negotiation program. Semaglutide (Ozempic and Wegovy) was included in the second round of negotiations for prices effective January 1, 2027. The negotiated price for Ozempic is approximately $274/month (versus a list price of ~$959) and Wegovy is approximately $385/month. Additionally, in late 2025 the Trump administration announced Most Favored Nation (MFN) pricing agreements with Novo Nordisk and Eli Lilly to lower list prices for Medicare and Medicaid beneficiaries, with Wegovy list prices falling to $675/month effective January 1, 2027.

• The FDA removed semaglutide from the shortage list in February 2025, triggering the legal wind-down of compounding pharmacy production.

• MASH indication: semaglutide received FDA accelerated approval for MASH with fibrosis in August 2025, expanding Wegovy's label significantly.

In Europe, the EMA approved Wegovy's cardiovascular indication in 2024. Several European national health systems are progressively expanding reimbursement but with cost-effectiveness requirements that limit coverage to higher-risk patients.

In international markets, regulatory timelines vary significantly. Japan, Australia, and Canada have moved faster; many emerging markets are still in early access phases.

Cyclicality

Pharmaceuticals are among the least cyclical industries. Patients with type 2 diabetes and obesity do not stop needing their medications during economic downturns. The primary economic sensitivity is the patient's ability to afford out-of-pocket costs - which affects adherence in high-cost commercial insurance markets but is mitigated by Novo Nordisk's co-pay assistance programs and the expanding payer coverage.

There is a non-obvious cyclical element in the U.S. policy environment: new administrations have historically taken different stances on drug pricing and Medicare coverage. The current environment (as of April 2026) features both price pressure (IRA negotiations, MFN agreements) and coverage expansion (BALANCE model, Medicare obesity coverage expansion). The net balance is uncertain.

Import Substitution and Biosimilars

Semaglutide patent expiry in certain international markets - specifically where data exclusivity periods are shorter - is an emerging headwind for 2026 and beyond. Management flagged "loss of semaglutide exclusivity in certain markets" as a 2026 headwind. In the U.S., the core patent portfolio is expected to provide protection through the late 2020s. Biosimilar competition for insulin products is already a reality (glargine biosimilars have compressed Levemir economics in the U.S.) and represents a structural headwind for the insulin franchise.

7. Growth Triggers

All triggers sourced directly from earnings call statements as noted.

• Oral Wegovy 25mg U.S. commercial launch: Launched January 2026 with approximately 50,000 weekly total prescriptions in the first week, with approximately 45,000 through self-pay cash channels. Management committed to expanding commercial insurance coverage through the year. > "The uptake is over twice that of any prior anti-obesity drug launches in the United States." (Dave Moore, Q4/FY 2025 call, February 4, 2026)

• Medicare Part D obesity coverage expansion mid-2026: Management guided for Medicare Part D coverage of anti-obesity medicines to begin mid-2026, opening access to an estimated 30 million Medicare-eligible obese patients. First mentioned as an upcoming catalyst on the Q4 2024 call (February 5, 2025) and repeated through Q3 2025 and FY 2025 calls as the most significant volume catalyst on the horizon. (Q4 2024 call Feb 5, 2025; Q3 2025 call Nov 5, 2025; FY 2025 call Feb 4, 2026)

• CagriSema FDA decision late 2026: Filed with the FDA in December 2025 based on REDEFINE 1 and REDEFINE 2 trials. Management guided for an FDA decision in late 2026. CagriSema (cagrilintide + semaglutide combination) showed 22.7% mean weight loss versus semaglutide's 16.1% in REDEFINE 1. New REDEFINE 11 trial initiated to explore higher weight loss potential with modified dosing protocol. (Q4 2024 call Feb 5, 2025 for data readout; FY 2025 call Feb 4, 2026 for filing confirmation)

• Semaglutide 7.2mg obesity Phase 3 development: Higher dose semaglutide (7.2mg versus 2.4mg) showed 20.7% weight loss in the STEP UP Phase 3 trial versus 17.5% for standard 2.4mg dose. Regulatory filing pathway under evaluation. (Q4 2024 call, February 5, 2025)

• Amycretin Phase 3 start in obesity and T2D (2026): Phase 3 trials for amycretin (unimolecular GLP-1 + amylin agonist) planned to begin 2026 in both obesity and type 2 diabetes. Phase 2 data showed 22% weight loss at highest dose over 36 weeks. (Q3 2025 call, November 5, 2025; FY 2025 call, February 4, 2026)

• Mim8 regulatory approvals (EU/Japan): Mim8 for haemophilia A filed in EU and Japan. EU decision expected 2026. If approved, it enters the haemophilia A inhibitor patient population previously served primarily by Hemlibra. (Q2 2024 call, August 7, 2024; Q3 2024 call, November 6, 2024)

• IcoSema combination approval: IcoSema (insulin icodec + semaglutide, once-weekly injection) filed in H2 2024 after COMBINE 1 Phase 3 success. Regulatory decisions in multiple markets pending. (Q2 2024 call, August 7, 2024)

• Semaglutide MASH indication commercial uptake: FDA approved semaglutide (Wegovy) for MASH with liver fibrosis in August 2025. Management described this as a meaningful new patient population, with hepatologists now a target prescriber group. Commercial coverage negotiations underway. (Anticipated on Q3 2024 call, November 6, 2024; confirmed FY 2025 context)

• Kidney disease label expansion for Ozempic: FLOW trial showed 24% reduction in major kidney disease events. Regulatory submission for expanded Ozempic kidney label in U.S. and EU underway. (Q1 2024 call, May 2, 2024; reiterated Q3 2024 call)

• International Wegovy rollout: Approximately 35 new country launches of Wegovy completed in 2025. Continued market development in Europe, Japan, Australia, and emerging markets drives structural International Operations volume growth. (Q3 2025 call, November 5, 2025; FY 2025 call, February 4, 2026)

• Compounding wind-down and rebrand conversion: As compounding pharmacies exit the market following the FDA shortage list removal and legal action, management guided for branded Wegovy prescription recovery in H2 2025 and 2026. The launch of direct-to-consumer platform NovoCare and partnerships with Hims & Hers, Ro, and LifeMD are designed to capture patients migrating off compounders onto branded products. (Q1 2025 call, May 7, 2025; Q2 2025 call, August 6, 2025)

8. Key Risks

Risk 1: IRA Price Compression - Direct Impact on Revenue Economics

Mechanism: The Inflation Reduction Act established a Medicare drug price negotiation process. Semaglutide was selected in Round 2, with Maximum Fair Prices (MFPs) effective January 1, 2027. The negotiated Ozempic price is approximately $274/month (a 71% reduction from list price of ~$959). The negotiated Wegovy price is approximately $385/month. Concurrently, MFN agreements negotiated by the Trump administration lower list prices to $675/month for semaglutide products from January 2027.

In practice, the MFP applies to Medicare Part D beneficiaries - which is not the entire market. Commercial insurance patients negotiate their own net prices through rebates. But approximately 30 million Medicare-eligible patients with obesity are expected to gain coverage starting mid-2026, meaning that the volume growth in Medicare comes at meaningfully lower net prices. Management included "lower realized prices" and "MFN pricing agreements" as the primary drivers of the -5% to -13% 2026 guidance. Novo Nordisk itself noted "significant concerns about how the law is being implemented, including aggregating multiple products that individually would not meet the statute's requirements" - a specific objection to the bundling of Ozempic, Wegovy, and Rybelsus under a single negotiation, which creates a combined threshold crossing that Novo argues is inappropriate.

Calibration: High probability, moderate magnitude. The mechanism is known and the impact is already factored into 2026 guidance. The risk is that the net price effect is larger than modeled (due to higher-than-expected Medicare volume mix) or that MFN-style pricing spreads to commercial insurance through "spillover" effects.

Risk 2: Competitive Displacement by Eli Lilly Tirzepatide

Mechanism: Tirzepatide's dual-agonist mechanism produces superior average weight loss (21% versus semaglutide's 17-18% at highest doses). Formulary decisions are increasingly favoring Zepbound over Wegovy in certain large PBM arrangements where Lilly offers more competitive rebates. Novo lost approximately 9 percentage points of global GLP-1 market share in the 12 months to Q3 2025. Lilly is also developing an oral GLP-1 (orforglipron, small molecule) that does not require a special absorption enhancer and may have manufacturing cost advantages.

"The obesity market is just significantly more dynamic than most other markets." (CFO Carsten Munk Knudsen, Q4 FY 2025 call, February 4, 2026)

If Lilly executes well on orforglipron approval and Novo's oral Wegovy fails to retain patients who prefer pills, the oral GLP-1 category could see a competitive shift similar to what happened in injectables. Additionally, Lilly has a broader pipeline of bispecific agonists (GLP-1/GIP/glucagon triple agonist - retatrutide - in Phase 3) that could widen the efficacy gap further.

Calibration: High probability of continued pressure. Moderate probability of significant market share loss that materially affects long-term revenue trajectory. The key mitigating factor is evidence breadth - Novo's SELECT/FLOW/SOUL/ESSENCE data gives it a cardiometabolic positioning story that tirzepatide does not yet have equivalently.

Risk 3: Pipeline Underperformance - CagriSema Disappointment

Mechanism: Novo Nordisk's most anticipated pipeline asset, CagriSema, missed its internal target of 25% weight loss in REDEFINE 1 (achieving 22.7%). The shortfall occurred partly because 43% of patients did not reach the highest dose due to tolerability issues under the flexible titration protocol. Novo Nordisk's stock fell approximately 20% on the December 2024 readout announcement.

The risk going forward is that FDA approval for CagriSema is denied, significantly delayed, or approved with labeling that limits its commercial positioning (e.g., if the FDA requires the tolerability data to be prominently labeled as a dosing limitation). Additionally, the REDEFINE 11 trial was initiated to explore modified dosing to achieve higher weight loss - this extends the development timeline and creates a competitor-advantage window.

Calibration: Moderate probability of a further setback (FDA may question dosing at trial end as representative), significant magnitude if it occurs. Amycretin is the backup with cleaner Phase 2 data but 5+ years to approval.

Risk 4: Compounding Pharmacies and Continued Illegal Activity

Mechanism: Even after the FDA shortage list removal and the legal wind-down deadlines (April/May 2025), Novo Nordisk's Q3 2025 call acknowledged that over 1 million U.S. patients were estimated to still be on compounded GLP-1s. Compounded semaglutide was available at $150-400/month versus Wegovy's ~$1,349 list price. The FDA has been inconsistent in enforcement, and some compounders pivoted to slightly modified formulations (e.g., adding B12 or niacin to branded compound mixes) to argue they are producing a "different" product not covered by the shortage list restrictions.

If compounding activity persists at scale - either through successful legal arguments or through regulatory inaction - it structurally impairs the U.S. branded volume recovery that underpins Novo Nordisk's 2026 guidance. It also creates patient safety concerns (quality and dose inconsistencies in compounded products) that generate litigation risk for Novo in cases where patients seek to claim brand products should have been available.

Calibration: High probability of ongoing residual compounding activity; moderate probability of material impact on branded volume recovery above what is already in guidance.

Risk 5: Patent Expiry and International Generic Entry

Mechanism: Semaglutide's core composition-of-matter patent expires in various jurisdictions across 2026-2030. In markets where data exclusivity periods are shorter (some emerging markets, potentially some EU markets for older indications), generic or biosimilar semaglutide could enter. Management flagged "loss of semaglutide exclusivity in certain international markets" as a specific 2026 headwind in the FY 2025 guidance disclosure.

The risk escalates post-2030 when U.S. patent coverage narrows. If biosimilar semaglutide enters the U.S. market before Novo Nordisk has successfully converted the market to next-generation products (CagriSema, Amycretin), the revenue base contracts rapidly.

Calibration: Currently low probability of U.S. impact (patent coverage extends through late 2020s), moderate probability of international impact in 2026-2028, high probability of eventual U.S. impact post-2030 if next-generation products are delayed.

Risk 6: 340B Program Litigation Outcome

Mechanism: The 340B Drug Pricing Program requires pharmaceutical manufacturers to sell drugs at a discount to qualifying healthcare organizations (hospitals and clinics serving vulnerable populations). A ruling from the U.S. Court of Appeals for the Seventh Circuit - pending as of Q3 2024 - could have "material impact" according to management's own language. If the ruling goes against Novo Nordisk, it could require retroactive payments or significantly expand the discounted distribution network, reducing effective net prices across a material portion of U.S. volume.

"One ruling from the U.S. Court of Appeals for the Seventh Circuit remains pending...may be subject to further discretionary appellate review before the U.S. Supreme Court, with potentially material financial impact." (Q3 2024 call, November 6, 2024)

Calibration: Moderate probability, potentially significant magnitude - management's use of "material" in both the Q3 2024 and Q4 2024 calls is a significant qualifier for a company of this scale.

Risk 7: Supply Chain Execution Risk on Massive Capex Program

Mechanism: Novo Nordisk is executing one of the most ambitious pharmaceutical manufacturing build-out programs in history - approximately $55-65 billion in annual capex for 2025-2026. The DKK 80 billion+ Kalundborg API expansion, three newly acquired Catalent sites, and multiple fill-and-finish expansions must all be commissioned on schedule to serve the demand growth the company is guiding. Construction delays, regulatory hold-ups in manufacturing site inspections, or technical problems in API synthesis scale-up could create supply constraints that limit commercial execution - precisely the dynamic that allowed Eli Lilly to gain market share in 2022-2023 when Novo was supply-constrained.

Calibration: Moderate probability of at least some delay in some site; manageable magnitude if only one or two projects slip, potentially significant if the main Kalundborg API expansion encounters problems.

Risk 8: Management Transition and Organizational Restructuring

Mechanism: Novo Nordisk announced in late 2024 that CEO Lars Fruergaard Jørgensen would step down, with Mike Doustdar appointed as new CEO. Simultaneously, the company announced a restructuring program eliminating approximately 9,000 positions (approximately 12% of the workforce) with DKK 8 billion in annual cost savings. Major leadership transitions during periods of acute commercial pressure (market share loss, pricing headwinds, pipeline underperformance) create execution risk. New strategy articulation, potential departures of key commercial and scientific talent, and organizational disruption could compound the operational challenges.

Calibration: Moderate probability of near-term execution disruption, lower probability of long-term strategic derailment given the strength of the foundation.

9. Walk the Talk

The most instructive way to assess Novo Nordisk management credibility is to track guidance from the Q1 2024 call through the FY 2025 call - an 8-quarter span covering both a period of exceptional performance and a significant deceleration.

Early 2024: Conservative Opening

On the Q1 2024 call (May 2, 2024), management set full year 2024 sales growth guidance at 19-27% at constant exchange rates. This was an unusually wide range - a 8 percentage point spread that CEO Lars Fruergaard Jørgensen attributed directly to "high growth volatility and regulatory caution." Analysts pushed back on the width; management held firm. The guidance was then raised sequentially: to 22-28% at H1 2024 (August 7), narrowed to 23-27% at Q3 2024 (November 6), and the full year came in at 26% - within every version of the guidance range, and at the upper half of the original range. This was an accurate conservative-to-midpoint guidance pattern, typical of a management team that builds in buffer and then manages toward it.

Specific Q1 2024 Commitments and Outcomes

In Q1 2024, management flagged two specific near-term catalysts: the Wegovy cardiovascular indication approval from the FDA (which had occurred in March 2024) and Medicare Part D coverage for the cardiovascular indication beginning to ramp. Both delivered on the Q1 call's timeline. The SELECT data's 20% MACE reduction was cited as the foundation; the subsequent commercial implication of approximately 4 million covered Medicare lives by Q1 2024 was accurately described as "early" with gradual growth expected. By FY 2024, Medicare coverage had expanded to approximately 55 million commercial lives, broadly in line with the trajectory management described.

The CagriSema Credibility Event

The most significant promise-versus-outcome gap in the four-call period is CagriSema. On the Q1 2024 call (May 2, 2024), management was asked directly about weight loss expectations. The response cited "25% weight loss" as the target for REDEFINE 1, based on Phase 1/2 modeling. This was reiterated on the Q2 2024 call (August 7, 2024) with "confidence level unchanged." The Q3 2024 call (November 6, 2024) maintained this framing ahead of the data readout.

The REDEFINE 1 data released in December 2024 showed 22.7% weight loss - a 2.3 percentage point miss versus the guided 25%. The stock fell approximately 20%. More damaging than the absolute number was the mechanistic explanation: only 57.3% of patients reached the highest dose, and those who did achieved approximately 25.1% weight loss. This revealed a tolerability issue in the flexible-titration protocol that Novo Nordisk had not adequately disclosed was a risk factor during the preceding three calls.

Management on Q3 2024 (Nov 6, 2024): "25% weight loss" projection based on internal modeling from Phase 1/2 data; confidence level unchanged pending Phase 3 results.

What happened: 22.7% mean weight loss. The promise was specific, repeated, and missed. To management's credit, they filed for FDA approval anyway in December 2025 rather than shelving the program, and they initiated REDEFINE 11 to test a modified protocol to achieve higher weight loss - acknowledging the dosing issue publicly. But the credibility cost of the specific 25% promise, repeated three times, was real.

2025: The Guidance Descent

This is where the pattern shifts and management credibility becomes more nuanced. At the Q4 2024 / FY 2024 call (February 5, 2025), management set 2025 guidance at 16-24% sales growth at constant exchange rates. This was below the 2024 run rate, explained by three factors: supply dynamics, competitive dynamics, and gross-to-net pricing normalization in the U.S.

CFO Knudsen on Q4 2024 call: "If you take that magnitude and apply it to a higher base, namely, this year's sales, and then adjust for the tailwind we've had from favorable U.S. gross to net adjustments related to prior years, then you end in the high teens."

By the Q1 2025 call (May 7, 2025), guidance was cut to 13-21% due to "lower than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the U.S." The CFO called compounding the "largest single factor" in the guidance revision. This was a genuine surprise - management's own Q4 2024 call had described compounding as "growing faster than we had anticipated" but the implication for 2025 branded volume was apparently worse than modeled.

At the Q2 2025 call (August 6, 2025), guidance was cut again to 8-14%. At Q3 2025 (November 5, 2025), it was narrowed to 8-11%. The full year 2025 delivered 10% sales growth - in the final guidance range but roughly at the lower half.

The pattern across 2025: management was consistently too optimistic about the compounding wind-down timeline and too slow to incorporate the impact into guidance. This is not an unusual pattern in pharmaceuticals when a regulatory action (shortage list removal) was expected to resolve a competitive dynamic faster than it did. But the three successive guidance cuts in Q1-Q3 2025 are a meaningful track record data point: in a year of genuine external uncertainty, management's initial guidance was not well-calibrated.

2026 Guidance: Unusually Transparent About Downside

The -5% to -13% guidance for 2026 - providing the first negative growth guidance in the company's modern history - is striking for its candor. CEO Mike Doustdar's framing was direct:

"Price reduction, in some ways, is our investment for the future and for capturing more patients."

This is an honest articulation of the volume-for-price trade-off. The management team is clearly aware that the 2026 number will look bad and has chosen to explain the mechanism rather than finesse it. The inclusion of both IRA/MFN pricing impacts and Medicaid coverage reductions as specific headlines shows a more granular disclosure than the compounding-related guidance misses of 2025.

Assessment

Novo Nordisk management is credible in long-term strategic narrative and accurate in directional guidance during stable periods. In 2024, the company delivered exactly what it guided. In 2025, it missed badly - three successive cuts driven by compounding underestimation. On pipeline, the CagriSema specific-percentage promise (25%) was a mistake; repeating a precise Phase 2-derived number three times before Phase 3 data creates unnecessary commitment to an outcome that biological variability will not reliably deliver. The new CEO's 2026 guidance disclosure is notably more forthright about headwinds than predecessor communications in early 2025. That is either cultural improvement or the new management team is setting a low bar to clear later. The 2026 numbers will be the first test of the new regime's calibration.

10. Scenarios

Bull Case: The Volume Machine Wins

Novo Nordisk enters 2027 having successfully converted the pricing headwind into a volume story. Oral Wegovy adoption in the U.S. accelerates through the year: the self-pay cash channel proves that patients are willing to pay $385/month for a branded pill, and commercial coverage expansions add millions of commercially insured patients who previously had no access. Medicare Part D obesity coverage begins mid-2026 and enrollment ramps faster than expected given the suppressed demand from the coverage gap. The company captures a meaningful share of the estimated 30 million Medicare-eligible obese patients.

CagriSema receives FDA approval in late 2026 with clean labeling, establishing a new efficacy benchmark above Wegovy in a distinct patient population. Physicians begin sequencing patients: start on Wegovy (or oral Wegovy), add CagriSema if sufficient weight loss is not achieved. This creates a pipeline within a pipeline - expanding the total addressable market for Novo's obesity products.

Compounding has fully wound down in the U.S. following sustained legal pressure and FDA enforcement. The telehealth partnerships (Hims & Hers, Ro, LifeMD) prove to be genuine conversion funnels for former compounders onto branded products. Novo's direct-to-consumer NovoCare platform builds a direct-pay channel that bypasses PBM rebate pressure.

Internationally, Wegovy launches in 30+ additional countries through 2026-2027. MASH emerges as a real commercial indication - hepatologists begin routinely prescribing Wegovy for MASH patients, a population previously treated by gastroenterologists with limited options. The Ozempic kidney label expansion drives nephrologist adoption.

In rare disease, Mim8 approval in the EU triggers a rapid share capture in the haemophilia A inhibitor population previously dominated by Hemlibra. The haemophilia franchise begins growing again after years of flat performance.

The Kalundborg API expansion completes on schedule in 2027, giving Novo Nordisk unconstrained supply headroom for the first time in its GLP-1 history. The company that was supply-limited becomes supply-advantaged. The massive capex program that pressured free cash flow in 2024-2026 begins generating returns.

Base Case: Price Pain, Then Recovery

The 2026 negative guidance materializes roughly as modeled. Net prices for semaglutide products fall as the MFN agreements and IRA prices take effect across the Medicare and Medicaid channels. Free cash flow drops to DKK 35-45 billion (from 75-85 billion in 2024), reflecting both price compression and ongoing capex.

Volume continues growing, offsetting part of the price decline. Oral Wegovy reaches sustained uptake of 100,000+ weekly prescriptions by end-2026, establishing itself as the preferred option for the large population of patients who are GLP-1-eligible but injection-averse. Medicare obesity coverage brings incremental access but enrollment is slower than the theoretical maximum due to prior authorization friction and physician unfamiliarity.

CagriSema is approved mid-to-late 2026 but faces a nuanced commercial launch: it is positioned for patients who failed Wegovy and need more weight loss, but reimbursement as a second-line agent is more complex to establish. The drug generates meaningful revenue in 2027 but does not immediately revive the top-line trajectory.

Eli Lilly retains its market share lead but does not dramatically extend it. Orforglipron (oral tirzepatide) reaches the market in 2026-2027 and competes with oral Wegovy, creating a two-pill market. Novo maintains its evidence library as a differentiator but accepts lower realized prices to defend volume.

By 2027-2028, the combination of price stabilization at new lower levels and volume growth produces a recovery in revenue trajectory. The restructuring program ($1.2 billion in annual savings) improves the operating margin profile. The manufacturing capex starts generating supply advantage in 2027-2028, allowing Novo to respond faster to demand surges.

The new CEO Mike Doustdar establishes strategic credibility by executing the restructuring without major talent exodus and by setting realistic guidance that is met.

Bear Case: The Compression Trap

The pricing headwinds prove worse than guided. MFN-style pricing spreads through commercial insurance channels as large employers and PBMs use the Medicare reference price as a negotiating lever in 2027 contract renewals. What management described as Medicare-specific price reductions start bleeding into commercial pricing. Realized net prices for semaglutide across all channels decline 30-40% over 2026-2027.

CagriSema receives an FDA complete response letter citing the dosing issue identified in REDEFINE 1 - specifically, the gap between full-dose and observed-dose effects. Novo initiates a new trial (REDEFINE 11) but the path to approval stretches to 2028-2029. Eli Lilly's retatrutide (triple agonist GLP-1/GIP/glucagon, showing 24%+ weight loss in Phase 3) is approved before CagriSema in its revised form, establishing a higher efficacy benchmark in the obesity market before Novo has a competitive next-generation agent.

Compounding does not fully resolve. A court ruling challenges FDA's authority to ban compounded semaglutide on shortage list removal, creating an 18-24 month legal uncertainty period during which compounders continue operating. The NovoCare/telehealth conversion strategy fails to capture a sufficient share of former compounders.

International markets face an earlier-than-expected wave of semaglutide biosimilars. Several European markets where data exclusivity is shorter see local manufacturers (particularly Indian and Chinese generic companies) begin producing lower-cost semaglutide generics, forcing Novo to dramatically cut international net prices ahead of the U.S. patent expiry timeline.

The DKK 55-65 billion annual capex creates an extended cash flow trough that limits Novo's ability to fund pipeline acquisitions (Metsera deal falls through due to balance sheet constraints), compresses dividend growth below historical rates, and reduces R&D spending flexibility. Amycretin - Novo's best-looking next-generation asset - faces development delays because Phase 3 trials are deferred to manage R&D costs.

The organizational restructuring (9,000 headcount reduction) creates execution disruption at precisely the moment it is most costly: commercial teams are distracted, key scientific talent leaves for Lilly and smaller biotech competitors, and the new CEO loses credibility from a missed 2026 guidance.

Sources:

• Novo Nordisk Q4 2024 Earnings Call Transcript - The Motley Fool
• Novo Nordisk Q3 2024 Earnings Call Transcript - The Motley Fool
• Novo Nordisk Q2 2024 Earnings Call Transcript - The Motley Fool
• Novo Nordisk Q1 2024 Earnings Call Transcript - The Motley Fool
• Novo Nordisk FY 2025 Earnings Call Transcript - Investing.com
• Novo Nordisk Q3 2025 Earnings Call - Investing.com
• Novo Nordisk Annual Report 2024
• Novo Nordisk Annual Report 2025 - Financial Performance
• Novo Nordisk 2025 Financial Report and 2026 Outlook - PharmExec
• GLP-1 Receptor Agonist Market Size Report - Grand View Research
• Novo Nordisk Lost GLP-1 Market Share - Syenza News
• CagriSema Falls Short of 25% Weight Loss - PharmExec
• Novo Nordisk Files NDA for CagriSema - Yahoo Finance
• FDA Removes Semaglutide from Shortage List - Foley & Lardner
• Medicare Negotiated Prices for Semaglutide - Fierce Pharma
• Novo Holdings Ownership Structure
• Catalent Acquisition Completion - GlobeNewswire
• FDA Approves Semaglutide for MASH - AJMC
• Novo Nordisk History - Wikipedia
• Novo Nordisk Rare Disease Products - US
• Obesity Market Outlook 2026 - IQVIA